Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 4, 2025 • 8:01 AM ET

Date/Time Source News Release
05/28/2025 06:35 AM EDT GlobeNewswire Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
05/26/2025 10:00 AM EDT GlobeNewswire Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
05/13/2025 07:05 AM EDT GlobeNewswire Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025
05/13/2025 06:35 AM EDT GlobeNewswire Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
05/07/2025 07:05 AM EDT GlobeNewswire Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)
05/06/2025 07:05 AM EDT GlobeNewswire Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
04/27/2025 03:00 PM EDT GlobeNewswire Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting
04/25/2025 07:35 AM EDT GlobeNewswire Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma
03/04/2025 06:35 AM EST GlobeNewswire Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
03/03/2025 07:30 AM EST GlobeNewswire Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
Page

Additional News

As of June 4, 2025 • 8:01 AM ET

Date/Time Source News Release
05/13/2025 01:14 PM EDT SeekingAlpha Y-mAbs Therapeutics outlines Q2 revenue guidance of $17M-$19M amid DANYELZA NCCN guideline inclusion and expanded ex-U.S. growth
05/13/2025 01:13 PM EDT SeekingAlpha Y-mAbs Therapeutics, Inc. (YMAB) Q1 2025 Earnings Call Transcript
05/13/2025 07:45 AM EDT Zacks Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
05/13/2025 07:00 AM EDT US Earnings Reports Expected US Company Earnings on Tuesday, May 13th, 2025
05/13/2025 06:37 AM EDT SeekingAlpha Y-mAbs Therapeutics beats top-line and bottom-line estimates; initiates Q2 and reaffirms FY outlook
05/13/2025 05:31 AM EDT US Earnings Reports Expected earnings - Y-mAbs Therapeutics Inc.
05/12/2025 08:15 AM EDT Zacks Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Lags Revenue Estimates
05/09/2025 08:35 AM EDT Zacks Anika Therapeutics (ANIK) Reports Q1 Loss, Misses Revenue Estimates
05/07/2025 06:15 PM EDT Zacks Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
05/07/2025 09:06 AM EDT SeekingAlpha Y-mAbs gets NCCN recommendation for neuroblastoma treatment
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.